Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era.
Source: [Fortune](https://fortune.com/2026/08/26/pancreatic-cancer-fda-approval-pill-doubles-survival-rate-revolution-medicines/)